Antiphospholipid syndrome: Association between laboratory tests and clinical practice

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 249-255

  Galli, Monica ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulants; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY;

ANTIBODY DETECTION; ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING TEST; CLINICAL PRACTICE; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; STANDARDIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; IMMUNOLOGIC TESTS; LUPUS COAGULATION INHIBITOR; THROMBOSIS;

EID: 14044279160     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083810     Document Type: Conference Paper

References (53)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-1311.
2. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HJ, Harris EN, Vilardel-Torres M, Hughes GR. The "primary" antiphospholipid syndrome; major clinical and serological features. Medicine (Baltimore) 1989;68:366-374.
3. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine 1989;68:353-365.
4. Triplett DA, Boffa MC. Lupus anticoagulant: detection, standardization and heterogenity. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y (eds.). The Antiphospholipid Syndrome II. Autoimmune thrombosis. Elsevier, Amsterdam, 2002, 23-28.
5. Pierangeli SS, Harris EN. Antibodies to cardiolipin and other phosholipids. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y (eds.). The Antiphospholipid Syndrome II. Autoimmune thrombosis. Elsevier, Amsterdam, 2002, 29-43.
6. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185-1190.
7. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda Vriesman PJC, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-1547.
8. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that include a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci (USA) 1990;87:4120-4127.
9. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-178.
10. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632.
11. Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992;68:297-300.
12. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486-491.
13. Willems G, Janssen MP, Pelsers MMAL, Comfurius P, Galli M, Zwaal RFA, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody- β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-13842.
14. Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RFA, Bevers EM. Kinetics of prothrombin-mediated binding of lupus anticoagulant antibodies to phosphatidylserine-containing phospholipid membranes: an ellipsometric study. Biochemistry 2002;41:14357-14363.
15. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998;79:79-86.
16. Field SL, Chesterman CN, Day YP, Hogg PJ. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid. J Immunol 2001;166:6118-6125.
17. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity. Thromb Haemost 1993; 70:342-345.
18. Permpkul P, Rao LVM, Rapaport SI: Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994;83:2878-2892.
19. Horbach DA, van Oort E, Derksen RHWM, de Groot PG. The contribution of anti-prothrombin antibodies to lupus anticoagulant activity: discrimination between functional and non-functional anti-prothrombin antibodies. Thromb Haemost 1998;79:790-795.
20. Simmelink MJA, Derksen RHWM, Arnout J, de Groot PG. A simple method to discriminate between β2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003;1:740-747.
21. Greaves M, Cohen H, Machin SI, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-715.
22. Roussi J, Roisin JP, Goguel A. Lupus anticoagulants. First French interlaboratory etalanorme survey. Am J Clin Pathol 1996;105:788-793.
23. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001;86:83-91.
24. Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK national external quality assessment scheme (NEQAS) for blood coagulation. Thromb Haemost 1997:77:934-937.
25. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TAL, Preston FE. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002;119:364-369.
26. Le Querrec A, Arnout J, Arnoux D, Borg JY, Caron C, Darnige L, Dalahousse B, Reber G, Sie P. Quantification of lupus anticoagulants in clinical samples using anti- β2-glycoprotein I and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001;86:584-589.
27. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European concerted action of thrombophilia (ECAT) survey using plasma spiked with monoclonal antibodies against human β2-glycoprotein I. Thromb Haemost 1999;81:929-934.
28. Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmarco M, Potron G. Multicenter evaluation of nine commercial kits for the quantification of anticardiolipin antibodies. Thromb Haemost 1995;73:444-452.
29. Harris EN, Gharavi AE, Patel S, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987;68:215-222.
30. Harris EN. The second international anticardiolipin standardization workshop/the Kingston Antiphospholipid Antibody study (KAPS) group. Am J Clin Pathol 1990;94:476-484.
31. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop: Vth International Symposium on antiphospholipid antibodies. Am J Clin Pathol 1994;101:616-624.
32. Pierangeli SS, Stewart M, Silva LK, Harris EN. Report of an anticardiolipin wet workshop during the VIIth International Symposium on antiphospholipid antibodies. J Rheumatol 1998;25:156-162.
33. Tincani A, Allegri F, Sanmarco M Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001;86:575-583.
34. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays. Am J Clin Pathol 2002;118:548-557.
35. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, Boffa MC, Arvieux J. Inter-laboratory variability of anti-β2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on antiphospholipid antibodies standardization group. Thromb Haemost 2002;88:66-73.
36. Donohoe S, Mackie JI, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001;113:544-549.
37. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infection. Clin Immunol Innumopathol 1986;41:8-15.
38. Sammaritano LR. Drug-induced antiphospholipid antibodies. In: Khamashta MA (ed.). Hughes sindrome. The antiphospholipid sindrome. Springer, London, 2000; pp 144-154.
39. Asherson RA. Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmunity 2000;15:117-122.
40. Santiago M, Martinelli R, Ko A, Reis EA, Fontes RD, Nascimento EG, Pierangeli S, Espinola R, Gharavi A. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol 2001;19:425-430.
41. Guerin J, Smith O, White B, Sweetman G, Feighery C, Jackson J. Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br J Haematol 1998;102:896-902.
42. Giordano P, Galli M, Del Vecchio GC, Altomare M, Norbis F, Ruggeri L, Petronelli M, de Mattia D. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassemia. Br J Haematol 1998;102:903-906.
43. El-Roey A, Gleicher N. Definition of normal autoantibody levels in apparently healthy population. Obstet Gynecol 1988;72:596-602.
44. Vila P, Hernandez MC, Lopez-Fernandez MF, Batle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209-213.
45. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987;69:557-565.
46. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989;16:623-625.
47. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and auticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20:231-236.
48. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003;101:1827-1832.
49. Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999;81:695-700.
50. Galli M, Dlott J, Norbis F, Ruggeri L, Cler L, Triplett DA, Barbui T. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost 2000;84:1012-1016.
51. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti β2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008-1014.
52. Simmelink MJA, Horbach DA, van Oort E, Derksen RHWM, deGroot PG. DRVVT is a much better predictor than KCT for the risk of thrombosis. Lupus 1998;7:S219.
53. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid sindrome. Blood 2003;102:2717-2723.